JP2020525436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525436A5 JP2020525436A5 JP2019570906A JP2019570906A JP2020525436A5 JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5 JP 2019570906 A JP2019570906 A JP 2019570906A JP 2019570906 A JP2019570906 A JP 2019570906A JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- compound
- dosage form
- gastric resistance
- resistance controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013270 controlled release Methods 0.000 claims 33
- 230000002496 gastric effect Effects 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000002552 dosage form Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229960003943 hypromellose Drugs 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- -1 hydroxypropoxy Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147484A JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523204P | 2017-06-21 | 2017-06-21 | |
| US62/523,204 | 2017-06-21 | ||
| PCT/US2018/038853 WO2018237207A1 (en) | 2017-06-21 | 2018-06-21 | Gastro-resistant controlled release oral dosage forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Division JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525436A JP2020525436A (ja) | 2020-08-27 |
| JP2020525436A5 true JP2020525436A5 (enExample) | 2021-07-29 |
Family
ID=62904624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570906A Pending JP2020525436A (ja) | 2017-06-21 | 2018-06-21 | 胃耐性制御放出経口剤形 |
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11464744B2 (enExample) |
| EP (1) | EP3641732A1 (enExample) |
| JP (3) | JP2020525436A (enExample) |
| CN (1) | CN111511353A (enExample) |
| AU (2) | AU2018290287B2 (enExample) |
| BR (1) | BR112019027398A2 (enExample) |
| CA (1) | CA3067031A1 (enExample) |
| CL (1) | CL2019003743A1 (enExample) |
| CO (1) | CO2019014496A2 (enExample) |
| IL (3) | IL271606B2 (enExample) |
| MX (1) | MX2023002994A (enExample) |
| PE (1) | PE20200732A1 (enExample) |
| UA (1) | UA127349C2 (enExample) |
| WO (1) | WO2018237207A1 (enExample) |
| ZA (1) | ZA202409847B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| IL271606B2 (en) | 2017-06-21 | 2024-05-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| CA3108882A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| CA3243767A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888340T2 (de) | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
| WO1991006297A1 (en) | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| JP3333878B2 (ja) | 1992-04-23 | 2002-10-15 | メレルダウファーマスーティカルズ インコーポレイテッド | セロトニン５ｈｔ２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途 |
| EP1260512B1 (en) | 2000-02-29 | 2007-07-04 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| DK1345595T3 (da) | 2000-09-29 | 2007-09-10 | Solvay Pharm Bv | Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse |
| BRPI0415953B8 (pt) | 2003-10-29 | 2021-05-25 | Wyeth Corp | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| WO2006131711A1 (en) | 2005-06-06 | 2006-12-14 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
| JP2009525979A (ja) | 2006-02-07 | 2009-07-16 | 田辺三菱製薬株式会社 | ４−アシルアミノピリジン誘導体を介した神経新生 |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CN101273982A (zh) | 2007-03-30 | 2008-10-01 | 田边三菱制药株式会社 | 预防和/或治疗抑郁症的药物 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| PL2471518T3 (pl) | 2009-05-18 | 2018-01-31 | Sigmoid Pharma Ltd | Kompozycja zawierająca kropelki oleju |
| TW201206502A (en) | 2010-06-16 | 2012-02-16 | Teijin Pharma Ltd | Controlled release nucleated tablet |
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| CA3154027A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals, Inc. | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
| RS64819B1 (sr) | 2010-07-20 | 2023-12-29 | Minerva Neurosciences Inc | Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma |
| US20120040008A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012123922A1 (en) | 2011-03-17 | 2012-09-20 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| CN104023725B (zh) * | 2011-08-16 | 2019-04-26 | 卡迪欧拉有限公司 | 控释制剂 |
| RU2015140610A (ru) * | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| CN104586771B (zh) * | 2013-10-30 | 2018-01-16 | 广州朗圣药业有限公司 | 一种盐酸坦洛新缓释微丸制剂 |
| MA39987A (fr) * | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| CN106687107B (zh) * | 2014-08-13 | 2020-12-25 | 西达-赛奈医疗中心 | 抗产甲烷组合物及其用途 |
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| JP6855469B2 (ja) * | 2015-10-16 | 2021-04-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 消化器標的療法のための処方物を調製するための工程 |
| TWI851224B (zh) | 2016-05-25 | 2024-08-01 | 日商田邊三菱製藥股份有限公司 | 非思覺失調症病患之負性症狀治療用醫藥組成物 |
| IL271606B2 (en) | 2017-06-21 | 2024-05-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| CA3108882A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| WO2020264486A1 (en) | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
| CA3243767A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA |
-
2018
- 2018-06-21 IL IL271606A patent/IL271606B2/en unknown
- 2018-06-21 PE PE2019002573A patent/PE20200732A1/es unknown
- 2018-06-21 UA UAA202000290A patent/UA127349C2/uk unknown
- 2018-06-21 AU AU2018290287A patent/AU2018290287B2/en active Active
- 2018-06-21 WO PCT/US2018/038853 patent/WO2018237207A1/en not_active Ceased
- 2018-06-21 IL IL319156A patent/IL319156A/en unknown
- 2018-06-21 CN CN201880054407.9A patent/CN111511353A/zh active Pending
- 2018-06-21 CA CA3067031A patent/CA3067031A1/en active Pending
- 2018-06-21 BR BR112019027398-0A patent/BR112019027398A2/pt active Search and Examination
- 2018-06-21 EP EP18740435.5A patent/EP3641732A1/en active Pending
- 2018-06-21 US US16/015,151 patent/US11464744B2/en active Active
- 2018-06-21 IL IL308650A patent/IL308650B2/en unknown
- 2018-06-21 JP JP2019570906A patent/JP2020525436A/ja active Pending
-
2019
- 2019-12-18 CL CL2019003743A patent/CL2019003743A1/es unknown
- 2019-12-18 MX MX2023002994A patent/MX2023002994A/es unknown
- 2019-12-20 CO CONC2019/0014496A patent/CO2019014496A2/es unknown
-
2022
- 2022-06-15 US US17/841,284 patent/US12048768B2/en active Active
-
2023
- 2023-09-12 JP JP2023147484A patent/JP2023175778A/ja active Pending
-
2024
- 2024-06-10 US US18/738,782 patent/US20250009665A1/en active Pending
- 2024-09-13 AU AU2024219717A patent/AU2024219717A1/en active Pending
- 2024-12-19 ZA ZA2024/09847A patent/ZA202409847B/en unknown
-
2025
- 2025-06-17 JP JP2025101290A patent/JP2025134828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525436A5 (enExample) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| FI117961B (fi) | Nopeasti vaikutuksen aloittava formulaatio | |
| CN110035757A (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| JP2015506377A5 (enExample) | ||
| JP2011513391A (ja) | ミコフェノラートを含有する徐放性医薬組成物およびその方法 | |
| JP2009525343A5 (enExample) | ||
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2016516698A5 (enExample) | ||
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP2015510916A5 (enExample) | ||
| JP2013529665A5 (enExample) | ||
| WO2014029953A1 (en) | Hot melt extruded (hme) pharmaceutical composition of cinacalcet | |
| AU2014279743B2 (en) | Modified release formulation | |
| EP2841061A1 (en) | Methods for treating cardiovascular disorder | |
| JP2015509539A5 (enExample) | ||
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2010538062A5 (enExample) | ||
| WO2018095996A1 (en) | Delayed release dosage forms comprising dimethyl fumarate | |
| WO2022138717A1 (ja) | 経口固形製剤 | |
| JP6854162B2 (ja) | 錠剤 | |
| JP6815109B2 (ja) | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| WO2017174096A1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof | |
| EP3796904A1 (en) | Sustained release acemetacin compositions |